TABLE 1.
Antibodies to PspA in serum
| Subject and PspA exposure | Mean age in days (SD)a | No. of subjects | GMC (95% CI)b
|
|
|---|---|---|---|---|
| PspA family 1 | PspA family 2 | |||
| Children | 47 | |||
| PspA family 1 exposure | 435 (148) | 16 | 1.26 (0.46, 3.44) | 0.56 (0.33, 0.97) |
| PspA family 2 exposure | 490 (153) | 15 | 0.60 (0.24, 1.52) | 1.23 (0.40, 3.77) |
| PspA family 1 and 2 exposures | 557 (173) | 16 | 2.30 (1.07, 4.95) | 2.88 (1.18, 7.02) |
| Adults | 60 | 5.47 (4.24, 7.06) | 5.71 (4.21, 7.75) | |
a
SD, standard deviation.
b
The geometric mean concentrations (GMCs) and 95% confidence intervals (CI) of serum PspA antibodies in the sera of children and adults. Only one serum per child was included in the comparison; the average ages of the children at the time the sera were collected are given. Children developed more antibodies to the same PspA family they had been exposed to, but the differences in mean anti-PspA1 and anti-PspA2 concentrations were not statistically significant (family 1, P = 0.059; family 2, P = 0.058; Student's t test, paired, two-tailed).